Results 91 to 100 of about 20,955 (176)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis

Clinical and Experimental Gastroenterology, 2014
Marisa Iborra,1 Diego Álvarez-Sotomayor,2 Pilar Nos1 1Gastroenterology Unit, Department of Digestive Disease, Centro de investigación biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), La Fe University and ...
Iborra M, Álvarez-Sotomayor D, Nos P   +2 more
doaj  

Lost in the Vaso‐Occlusion: A Patient's Abdominal Pain Returns With a Vengeance

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
Dunia Hatabah, Martha E. Stewart, Nathan Maassel, James P. Stevens, Claudia R. Morris, Chris A. Rees   +5 more
wiley   +1 more source

Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes

Patient Related Outcome Measures, 2011
Richard D O'ConnorSharp Rees-Stealy Medical Group, San Diego, CA, USAAbstract: In the United States, budesonide/formoterol pressurized metered-dose inhaler (pMDI) is approved for treatment of asthma in patients aged ≥12 years whose asthma ...
Richard D O'Connor
doaj  

Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis

Pharmaceuticals
Eosinophilic Esophagitis is an antigen-mediated inflammatory disease characterized by thickening of the esophageal wall, leading to dysphagia, vomiting, reflux, and abdominal pain. This disease can be treated with a therapeutic approach ranging from diet
Antonio Spennacchio, Antonio Lopalco, Giuseppe Francesco Racaniello, Annalisa Cutrignelli, Flavia Maria la Forgia, Sergio Fontana, Fernanda Cristofori, Ruggiero Francavilla, Angela Assunta Lopedota, Nunzio Denora   +9 more
doaj   +1 more source

Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study

Therapeutic Advances in Gastroenterology
Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes.
Stephanie Coward, Karen J. B. Martins, Scott Klarenbach, Lawrence P. Richer, Christopher Ma, Remo Panaccione, Cynthia H. Seow, Karen Kroeker, Frank Hoentjen, Laura E. Targownik, Gilaad G. Kaplan   +10 more
doaj   +1 more source

Cost-effectiveness of anti-inflammatory reliever (AIR) or maintenance and reliever therapy (MART) for mild to moderate asthma: a systematic review. [PDF]

BMJ Open Respir Res
Ndimande N, Mortimer K, Stolbrink M, Mbonigaba J, Marozva N, Masekela R.   +5 more
europepmc   +1 more source

Differential Enteric Glial and Mast Cell Characteristics Distinguish Microscopic Colitis Subtypes Relative to Healthy and Disease Controls, with Treatment-Associated Reductions in Glial Reactivity and Mast Cell Degranulation in Collagenous Colitis. [PDF]

Cells
Beaudeau J, Escudero-Hernández C, Abruzzese V, Katinios G, Orell G, Barazanji N, Walter S, Hjortswang H, Kiudelis V, Kupčinskas J, Münch A, Keita ÅV.   +11 more
europepmc   +1 more source

Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B. [PDF]

Int J Mol Sci
Herbst K, Pezeshkpoor B, Klein C, Albert T, Lutz P, Strassburg C, Spengler U, Goldmann G, Oldenburg J.   +8 more
europepmc   +1 more source

Comparison of Selected Therapies Within the Step-Up Therapeutic Approach in Canine Chronic Inflammatory Enteropathy. [PDF]

Animals (Basel)
Kunay L, Fialkovičová M, Benková M, Tóthová C, Kořená N, Gomulcová S, Vargová M, Micháľová A, Lukáč B, Bielik B, Staroňová R.   +10 more
europepmc   +1 more source

Impact of Regional Hepatic Immunosuppression With Budesonide on Bacterial Elimination in Porcine Abdominal Sepsis. [PDF]

Acta Anaesthesiol Scand
Hanslin K, Skorup P, Wilske F, Larsson A, Tano E, Sjölin J, Lipcsey M.   +6 more
europepmc   +1 more source